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Figure 1. Kaposi sarcoma in the right eye before received 
HAART
Figure 2. Kaposi sarcoma lesion was improved  approximately 
within 1.5 months of Truvada® (emtricitabine and tenofovir 
disoproxil fumarate) and efavirenz therapy
Figure 3. Kaposi sarcoma lesion was healed within approximately 3.5 months of Truvada® (emtricitabine and tenofovir disoproxil 
fumarate) and efavirenz therapy
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Kaposi sarcoma defined as a multifocal 
lesion in mucocutaneous sites which has low-
grade malignant potential. Kaposi sarcoma 
also commonly found in visceral organs.1 This 
malignancy is very popular among elderly 
men before the epidemic of HIV/AIDS in 
the decade of 1980-1990.2 Kaposi sarcoma 
known to be associated with immunodeficiency 
state as in HIV/AIDS patients.3 Nowdays, 
incidence of Kaposi sarcoma has decreased in 
developed countries in the era of Highly Active 
Antiretroviral Therapy (HAART),4 but still a big 
problem in resource-limited areas such as Sub-
Saharan Africa.5
Eye is an unusual location for Kaposi 
sarcoma.1 There are not many study published 
about eye involvement of Kaposi sarcoma. 
Kaposi sarcoma of the conjunctiva and ocular 
adnexa has been reported to be strongly 
associated with HIV/AIDS patients.1 An old 
case report published Kaposi sarcoma in the 
eye of HIV negative patient, which stated as a 
unique case because of his good immunological 
performance.6 It is reported from the study of 
HIV/AIDS patients in Argentina that Kaposi 
sarcoma in the eye found in 0,25% patients.1
This is a case of a young gay man/homosexual 
who has been previously diagnosed HIV/AIDS 
with absolute CD4 18 cells/uL. He has a lesion 
in his right conjunctiva describe as a red, edema/
swelling non-tender nodule (Figure 1). He 
also has a similar tumour in his neck below 
his right ear and also in his belly. It is clearly 
diagnosed from clinical appearance and MRI 
of the orbita that he has Kaposi sarcoma in his 
right conjunctiva. The result of biopsy on the 
tumor below the right ear resulted as a Sarcoma 
kaposi with further examination showed a 
hemangio-endhotelioma, intermediate, negative 
inmmunohistochemical staining for EGFR so 
therefore not eligible for anti EGFR targeting 
therapy. After a carefully evaluation he was 
put on HAART and within approximately 1.5 
months of Truvada® (emtricitabine and tenofovir 
disoproxil fumarate) and efavirenz therapy, the 
nodule was reduced significantly (Figure 2), and 
by 3.5 months, the lesion was healed (Figure 
3). Similar response found on the mass below 
his right ear.
Kaposi sarcoma is one of the most popular 
neoplasm found in HIV/AIDS patients.3,4 
Epidemiologic studies revealed that homosexual 
and bisexual HIV/AIDS patients have higher 
incidence of Kaposi sarcoma than intravenous 
drug user HIV/AIDS patients.3 It is first described 
by Moritz Kaposi, a Hungarian dermatologist 
in 1872.2 Kaposi sarcoma is described as 
an idiopathic multiple pigmented sarcoma. 
Kaposi sarcoma has several manifestations, 
i.e. mucocutaneous, nodal, oral, and visceral 
presentation.3 Kaposi sarcoma in the eye is 
included as a mucocutaneous nodal. The lesion 
can be plaque-like, nodal, and may be ulcerated, 
bleed, and become a focus of secondary bacterial 
infection.3
The pathogenesis of AIDS-related Kaposi 
sarcoma is related with cytokines expression. 
HIV infection cause immune dysregulation by 
altering the expression of cytokines, including 
IL-1, TNF-α, and IL-6. In the in vitro studies, it 
has been shown that cytokines secrete a number 
of angiogenic growth factors (basic fibroblast 
growth factor). These factors, along with HIV 
proteins, induce and proliferate cells to become 
sarcoma cells. Integrins and apoptosis process 
are important factors for the proliferation and 
neovascularization of Kaposi sarcoma tumour 
cells.3
  Kaposi sarcoma can be treated locally 
with intralesional vinblastine or bleomycin, 
radiotherapy, and electrochemoterapy. 
Systemic therapy include HAART and systemic 
chemotherapy such as with daunorubicin and 
pegylated liposomal doxorubicin.4 Evidences 
shown that incidence of Kaposi sarcoma 
was reduced in resource-rich countries with 
the estimated range between 33-95%.4 This 
phenomenon is related to the availability and 
the global use of HAART. But, more concern 
and action must be done in Sub-Saharan Africa 
because of the high incidence of HIV/AIDS and 
Kaposi sarcoma, and it’s minimal availability to 
HAART.
The use of HAART can reconstruct immune 
system with resulting increase of CD4 count and 
reduce of opportunistic infections. HAART also 
stated has an anti-angiogenic effect.7 HAART 
reduce HIV proteins and create better milieu to 
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the cytokines, with the clinical result decrease 
the incidence and heal Kaposi sarcoma lession.7 
In many cases, just giving HAART can heal 
Kaposi sarcoma without local and systemic 
chemotherapy treatment. Our patient from 
benefit the effect of HAART by healing the 
Kaposi nodule in his conjunctiva and now his 
absolute CD4 reached 386.
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